<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: potential licensing transactions", fill: "#800080"},
{source: "6: potential licensing transactions", target: "6: raise additional capital", fill: "#800080"},
{source: "6: raise additional capital", target: "6: fund research", fill: "#800080"},
{source: "6: fund research", target: "6: commercialize", fill: "#800080"},
{source: "6: commercialize", target: "6: product candidates", fill: "#800080"},
{source: "6: product candidates", target: "6: enhance existing services", fill: "#800080"},
{source: "6: enhance existing services", target: "6: competitive pressures", fill: "#800080"},
{source: "6: competitive pressures", target: "6: complementary businesses", fill: "#800080"},
{source: "6: complementary businesses", target: "6: technologies", fill: "#800080"},
{source: "6: potential licensing transactions", target: "8: raise necessary funds through public", fill: "#800080"},
{source: "8: raise necessary funds through public", target: "8: private equity", fill: "#800080"},
{source: "8: private equity", target: "8: offerings debt financings", fill: "#800080"},
{source: "8: offerings debt financings", target: "8: additional strategic alliances", fill: "#800080"},
{source: "8: additional strategic alliances", target: "8: arrangements", fill: "#800080"},
{source: "8: raise necessary funds through public", target: "13: actions would likely reduce", fill: "#0f0"},
{source: "13: actions would likely reduce", target: "13: common stock", fill: "#0f0"},
{source: "13: actions would likely reduce", target: "16: December ", fill: "#f0fff0"},
{source: "16: December ", target: "16: accumulated deficit", fill: "#f0fff0"},
{source: "16: accumulated deficit", target: "16: approximately", fill: "#f0fff0"},
{source: "16: approximately", target: "16: additional", fill: "#f0fff0"},
{source: "16: additional", target: "16: development activities", fill: "#f0fff0"},
{source: "16: December ", target: "21: dependent on", fill: "#0f0"},
{source: "21: dependent on", target: "21: collaborative arrangements with third parties", fill: "#0f0"},
{source: "21: collaborative arrangements with third parties", target: "21: development", fill: "#0f0"},
{source: "21: development", target: "21: commercialization activities may", fill: "#0f0"},
{source: "21: commercialization activities may", target: "21: successful collaborative arrangements", fill: "#0f0"},
{source: "21: dependent on", target: "START_HERE", fill: "#0f0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NASTECH PHARMACEUTICAL CO INC      ITEM 1A RISK FACTORS             You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below before making     an <font color="blue"><font color="blue">investment</font> decision</font></td>
    </tr>
    <tr>
      <td>We do not generate operating income and will require <font color="blue"><font color="blue">additional</font> financing</font> in     the future</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">additional</font> capital</font> is not available, we may have to curtail     or <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>Our business currently does not generate the cash that is <font color="blue">necessary</font> to     finance  our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We incurred losses from <font color="blue">operations</font> (excluding     interest income/expense and other income/expense) of dlra6dtta2 million in 2003,     dlra28dtta5 million in 2004 and dlra33dtta8 million in 2005</td>
    </tr>
    <tr>
      <td>Subject to the success of     our <font color="blue"><font color="blue">development</font> programs</font> and <font color="blue">potential <font color="blue">licensing <font color="blue">transactions</font></font></font>, we will need     to raise <font color="blue"><font color="blue">additional</font> capital</font> to <font color="blue">fund research</font> and <font color="blue">development</font>, to develop and     <font color="blue">commercialize</font> our <font color="blue"><font color="blue">product candidate</font>s</font>, to <font color="blue">enhance existing services</font>, to     respond to <font color="blue"><font color="blue">competitive</font> pressures</font> and to acquire <font color="blue">complementary businesses</font> or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital</font> needs <font color="blue">depend on</font> many factors, including:         •  the scope, duration and <font color="blue"><font color="blue">expenditures</font> associated with</font> our research and     <font color="blue"><font color="blue">development</font> programs</font>;         •  <font color="blue">continued scientific</font> progress in these programs;         •  the outcome of <font color="blue">potential <font color="blue">licensing <font color="blue">transactions</font></font></font>, if any;         •  <font color="blue">competing technological <font color="blue">development</font>s</font>;                                         25       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>  •  our <font color="blue"><font color="blue">proprietary</font> patent position</font>, if any, in our products; and         •  the <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font> process</font> for our products</td>
    </tr>
    <tr>
      <td>We may seek to raise <font color="blue">necessary</font> funds through public or <font color="blue">private equity</font>     offerings, debt financings or <font color="blue"><font color="blue">additional</font> strategic alliances</font> and licensing     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue"><font color="blue">additional</font> financing</font> on terms     favorable to us, if at all</td>
    </tr>
    <tr>
      <td>General <font color="blue">market conditions may</font> make it very     <font color="blue">difficult</font> for us to <font color="blue">seek financing from</font> the <font color="blue">capital markets</font></td>
    </tr>
    <tr>
      <td>We may be     required to <font color="blue">relinquish rights</font> to our <font color="blue">technologies</font> or <font color="blue">drug <font color="blue">candidates</font></font>, or     <font color="blue">grant licenses on terms</font> that are not favorable to us in order to raise     <font color="blue">additional</font> funds through alliance, joint venture or licensing <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If  adequate  funds are not available, we may have to delay, reduce or     <font color="blue">eliminate one</font> or more of our research or <font color="blue"><font color="blue">development</font> programs</font> and reduce     <font color="blue">overall overhead expenses</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">actions would likely reduce</font> the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">been profitable on</font> an <font color="blue">annual basis</font> for <font color="blue">nine years</font>, and we may     <font color="blue">never become profitable</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred net losses</font> in each of the past <font color="blue">nine years</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31,  2005,  we  had  an  <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra115dtta6 million and expect <font color="blue">additional</font> operating losses in the future as we     continue our research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>The process of developing our products requires <font color="blue"><font color="blue">significant</font> research</font>     and <font color="blue"><font color="blue">development</font> efforts</font>, including basic research, pre-clinical and clinical     <font color="blue">development</font>, as well as FDA <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font>, together     with  our  sales, marketing, general and <font color="blue">administrative expenses</font>, have     resulted in operating losses in the past, and there can be no assurance that     we  can  achieve  <font color="blue">profitability</font>  in the future</td>
    </tr>
    <tr>
      <td>Our ability to achieve     <font color="blue">profitability</font> depends on our ability, alone or with our <font color="blue">collaborators</font>, to     develop our <font color="blue">drug <font color="blue">candidates</font></font>, conduct <font color="blue">clinical trials</font>, obtain <font color="blue">necessary</font>     <font color="blue"><font color="blue">regulatory</font> approval</font>s, and <font color="blue">manufacture</font>, distribute, market and sell our drug     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be <font color="blue">successful at</font> any of these     <font color="blue">activities</font> or predict when we <font color="blue">will ever become profitable</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> our <font color="blue">collaborative</font> <font color="blue">arrangements</font> with <font color="blue">third parties</font> for a     substantial portion of our revenue, and our <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">activities</font> may be delayed or reduced if we fail to     negotiate or maintain successful <font color="blue">collaborative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue"><font color="blue">dependent</font> on</font> our current and any other <font color="blue">possible future</font>     <font color="blue">collaborators</font> to <font color="blue">commercialize</font> many of our <font color="blue"><font color="blue">product candidate</font>s</font> and to provide     the <font color="blue">regulatory</font> compliance, sales, marketing and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>     required for the success of our business</td>
    </tr>
    <tr>
      <td>If we fail to secure or maintain     successful <font color="blue">collaborative</font> <font color="blue">arrangements</font>, our <font color="blue">development</font> and <font color="blue">commercialization</font>     <font color="blue">activities</font> will be delayed or reduced and our <font color="blue">revenues will</font> be <font color="blue">materially</font>     and <font color="blue"><font color="blue">adversely</font> impacted</font></td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">entered into</font> <font color="blue">collaboration</font> <font color="blue">partnerships</font> with</font> P&amp;G in January 2006,     Merck  in  <font color="blue">September  </font>2004 and <font color="blue"><font color="blue"><font color="blue">Par Pharmaceutical</font> </font>in October </font>2004</td>
    </tr>
    <tr>
      <td>The     <font color="blue">strategic <font color="blue">collaboration</font></font> that we <font color="blue"><font color="blue">entered into</font> with</font> <font color="blue">Merck in September </font>2004     for PYY was <font color="blue">terminated on</font> March 1, 2006</td>
    </tr>
    <tr>
      <td>Over the next several years, we     will <font color="blue">depend on</font> these types of <font color="blue">collaboration</font> <font color="blue">partnerships</font> for a <font color="blue">significant</font>     portion of our revenue</td>
    </tr>
    <tr>
      <td>The expected <font color="blue">future milestone payments</font> and cost     <font color="blue">reimbursement</font>s from <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> will provide an important     source of financing for our research and <font color="blue"><font color="blue">development</font> programs</font>, thereby     <font color="blue">facilitating</font>  the <font color="blue">application</font> of our <font color="blue">technology</font> to the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font></font> can be     <font color="blue">terminated either by us</font> or by our <font color="blue">partners at</font> their <font color="blue">discretion upon</font> the     <font color="blue">satisfaction</font> of certain notice <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Our partners are not precluded     <font color="blue">from <font color="blue">in<font color="blue">dependent</font>ly</font> pursuing <font color="blue">competing products</font></font> and <font color="blue">drug delivery approaches</font>     or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">partners continue</font> their <font color="blue">contributions</font> to our     <font color="blue">collaborative</font> <font color="blue">arrangements</font>, they <font color="blue">may nevertheless</font> determine not to actively     pursue the <font color="blue">development</font> or <font color="blue">commercialization</font> of any resulting products</td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">partners may</font> fail</font> to perform their <font color="blue">obligations</font> under the <font color="blue">collaborative</font>     <font color="blue">arrangements</font> or may be slow in performing their <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>In addition,     our <font color="blue">partners may</font> experience financial <font color="blue">difficult</font>ies at any time that could     prevent  them  from  having  available  funds  to  contribute to these     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">collaboration</font> partners fail to conduct their     <font color="blue">commercialization</font>,  <font color="blue">regulatory</font>  compliance,  sales  and  marketing  or     <font color="blue">distribution</font> <font color="blue">activities</font> <font color="blue">successfully</font> and in a <font color="blue">timely manner</font>, we will earn     little or <font color="blue">no revenue from</font> those products and we will not be able to achieve     our <font color="blue">objectives</font> or build a sustainable or profitable business</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>Our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree upon the <font color="blue">commercial success</font> of     <font color="blue">products <font color="blue">manufacture</font>d by us pursuant</font> to <font color="blue">supply <font color="blue"><font color="blue">agreement</font>s</font></font> or <font color="blue">marketed by</font> our     <font color="blue">collaboration</font> partners</td>
    </tr>
    <tr>
      <td>Even if we are able to develop products and obtain the <font color="blue">necessary</font>     <font color="blue"><font color="blue">regulatory</font> approval</font>s, our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree on the     commercial  success  of <font color="blue">products <font color="blue">manufacture</font>d by us pursuant</font> to supply     <font color="blue"><font color="blue">agreement</font>s</font> or <font color="blue">marketed by</font> our <font color="blue">collaboration</font> partners</td>
    </tr>
    <tr>
      <td>If these products fail     to  achieve  or  <font color="blue">subsequently</font> maintain <font color="blue">market acceptance</font> or commercial     viability, our business would be <font color="blue">significant</font>ly harmed because our revenue is     <font color="blue"><font color="blue">dependent</font> upon sales</font> of these products</td>
    </tr>
    <tr>
      <td>Even if we are successful in <font color="blue">commercializing</font> a <font color="blue">product candidate</font>, it is     possible that the <font color="blue">commercial opportunity</font> for intranasally-<font color="blue"><font color="blue">administer</font>ed</font>     <font color="blue">products will</font> be limited</td>
    </tr>
    <tr>
      <td>None of our <font color="blue"><font color="blue">product candidate</font>s</font> utilizing our <font color="blue">intranasal drug</font> delivery     <font color="blue">technology</font> have been brought to market except <font color="blue">for Nascobal </font>nasal gel and     Nascobal <font color="blue">nasal spray</font></td>
    </tr>
    <tr>
      <td>Accordingly, while we believe there is a commercial     market  for  our  <font color="blue">intranasal drug</font> delivery <font color="blue">technology</font>, there can be no     assurance that our <font color="blue">intranasal drug</font> delivery <font color="blue">technology</font> will become a viable     <font color="blue">commercial alternative</font> to other <font color="blue">drug delivery methods</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors may</font>     affect  the  <font color="blue">market acceptance</font> and <font color="blue">commercial success</font> of any potential     products, including:         •  <font color="blue">establishment</font> and <font color="blue">demonstration</font> of the <font color="blue">effectiveness</font> and safety of the     drugs;         •  timing of <font color="blue">market entry as compared</font> to <font color="blue"><font color="blue">competitive</font> products</font>;         •  the benefits of our <font color="blue">drugs relative</font> to their prices and the <font color="blue">comparative</font>     price of <font color="blue">competing products</font>;          •   actual and perceived benefits and <font color="blue">detriments</font> of <font color="blue">intranasal drug</font>     delivery, which may be <font color="blue">affected by press</font> and <font color="blue">academic literature</font>;         •  marketing and <font color="blue"><font color="blue">distribution</font> support</font> of our products; and         •  any <font color="blue"><font color="blue">restrictions</font> on labeled <font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Our revenues and <font color="blue">profits from</font> any <font color="blue">particular generic <font color="blue"><font color="blue">pharmaceutical</font> products</font></font>     <font color="blue">decline as</font> our <font color="blue"><font color="blue">competitors</font> introduce</font> their own <font color="blue">generic equivalents</font></td>
    </tr>
    <tr>
      <td>On October 22, 2004, we <font color="blue">entered into</font> a license and <font color="blue">supply <font color="blue">agreement</font></font>     granting <font color="blue"><font color="blue">Par Pharmaceutical</font> </font>the exclusive US <font color="blue">distribution</font> and marketing     rights to our generic calcitonin-salmon intra<font color="blue">nasal spray</font></td>
    </tr>
    <tr>
      <td>Under the terms of     the  <font color="blue">agreement</font>  with  <font color="blue">Par Pharmaceutical</font>, we will obtain FDA approval,     <font color="blue">manufacture</font> and supply finished generic calcitonin-salmon intra<font color="blue">nasal spray</font>     to <font color="blue">Par Pharmaceutical</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Par Pharmaceutical</font> </font><font color="blue">will distribute</font> the product in the     United  States</td>
    </tr>
    <tr>
      <td>Novartis,  the  supplier of branded calcitonin-salmon     intra<font color="blue">nasal spray</font>, may introduce a generic version through Sandoz US, its     wholly-owned  subsidiary and Apotex has filed a generic <font color="blue">application</font> of     intranasal salmon-calcitonin with a <font color="blue">filing date</font> that has <font color="blue">priority over</font> our     ANDA   See  Item 1:  Business —  Collaborations  and  Programs —  Par     Pharmaceutical  Partnership</td>
    </tr>
    <tr>
      <td>Selling prices of <font color="blue">generic drugs typically</font>     decline, sometimes dramatically, as <font color="blue">additional</font> companies receive approvals     for a <font color="blue">given product</font> and <font color="blue"><font color="blue">competition</font> intensifies</font></td>
    </tr>
    <tr>
      <td>To the extent that our     <font color="blue">collaboration</font> partner and we succeed in being the first to market a generic     version  of a <font color="blue">significant</font> product, our <font color="blue">initial sales</font> and <font color="blue">profitability</font>     following the <font color="blue">introduction</font> of <font color="blue"><font color="blue">such product</font> will</font> be subject to material     <font color="blue">reduction upon</font> a competitor’s <font color="blue">introduction</font> of the <font color="blue">equivalent product</font></td>
    </tr>
    <tr>
      <td>Our     ability to sustain our sales and <font color="blue">profitability</font> on any <font color="blue">product over</font> time is     <font color="blue"><font color="blue">dependent</font> on</font> both the number of <font color="blue">new <font color="blue">competitors</font></font> for <font color="blue">such product</font> and the     timing of their approvals</td>
    </tr>
    <tr>
      <td>Clinical trials of our <font color="blue"><font color="blue">product candidate</font>s</font> are expensive and time-consuming,     and the results of these trials are uncertain</td>
    </tr>
    <tr>
      <td>Many of our research and <font color="blue"><font color="blue">development</font> programs</font> are at an early stage</td>
    </tr>
    <tr>
      <td>Clinical trials in patients are long, expensive and <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>The     length of time <font color="blue"><font color="blue">generally</font> varies <font color="blue">substantially</font> according</font> to the type of drug,     <font color="blue">complexity</font> of clinical trial design, <font color="blue">regulatory</font> compliance <font color="blue"><font color="blue">requirement</font>s</font>,     <font color="blue">intended use</font> of the <font color="blue">drug candidate</font> and rate of <font color="blue">patient enrollment</font> for the     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> not be commenced                                         27       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>or completed on schedule, <font color="blue">and the FDA </font>may not <font color="blue">ultimately approve</font> our product     <font color="blue">candidates</font>  for  commercial  sale</td>
    </tr>
    <tr>
      <td>Further, even if the results of our     pre-clinical  studies or <font color="blue">clinical trials</font> are initially positive, it is     possible that we will obtain <font color="blue">different</font> results in the <font color="blue">later stages</font> of drug     <font color="blue">development</font> or that results seen in <font color="blue">clinical trials</font> will not <font color="blue">continue with</font>     <font color="blue">longer term treatment</font></td>
    </tr>
    <tr>
      <td>Drugs in late stages of clinical <font color="blue">development</font> may fail     to show the desired safety and efficacy traits despite having progressed     through initial clinical testing</td>
    </tr>
    <tr>
      <td>For example, positive results in early     <font color="blue">Phase I or Phase II </font><font color="blue">clinical trials</font> may not be repeated in larger Phase II     or Phase III <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>All of our potential <font color="blue">drug <font color="blue">candidates</font></font> are prone     to the risks of <font color="blue">failure inherent</font> in drug <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trials</font> of     any or all of our drugs or <font color="blue">drug <font color="blue">candidates</font></font>, including PYY intra<font color="blue">nasal spray</font>,     PTH[(1-34)],  generic  calcitonin-salmon intra<font color="blue">nasal spray</font>, insulin and     morphine  <font color="blue">gluconate could</font> be <font color="blue">unsuccessful</font>, which would prevent us from     <font color="blue">commercializing</font> these drugs</td>
    </tr>
    <tr>
      <td>The FDA conducts its own in<font color="blue">dependent</font> analysis     of some or all of the pre-clinical and <font color="blue">clinical trial data submitted</font> in a     <font color="blue">regulatory</font> filing and <font color="blue">often comes</font> to <font color="blue">different</font> and <font color="blue">potentially</font> more negative     <font color="blue">conclusions than</font> the analysis performed by the <font color="blue">drug sponsor</font></td>
    </tr>
    <tr>
      <td>Our failure to     develop  safe,  <font color="blue">commercially</font>  viable  drugs  <font color="blue">approved by</font> the FDA would     <font color="blue">substantially</font>  impair our ability to <font color="blue">generate revenues</font> and sustain our     <font color="blue">operations</font> and would <font color="blue">materially</font> harm our business and <font color="blue"><font color="blue">adversely</font> affect</font> our     stock price</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">significant</font> delays in <font color="blue">clinical trials</font> will impede     our ability to seek <font color="blue"><font color="blue">regulatory</font> approval</font>s, <font color="blue">commercialize</font> our <font color="blue">drug <font color="blue">candidates</font></font>     and generate revenue, as well as <font color="blue">substantially</font> increase our <font color="blue">development</font>     costs</td>
    </tr>
    <tr>
      <td>We are subject to extensive <font color="blue"><font color="blue">government</font> regulation</font> including the <font color="blue">requirement</font>     of approval before our <font color="blue">products may</font> be <font color="blue">manufacture</font>d or marketed</td>
    </tr>
    <tr>
      <td>We, our <font color="blue">collaboration</font> partners, and our <font color="blue"><font color="blue">product candidate</font>s</font> are subject     to extensive <font color="blue">regulation by <font color="blue">government</font>al authorities</font> in the US and other     countries</td>
    </tr>
    <tr>
      <td>Failure to comply with applicable <font color="blue"><font color="blue">requirement</font>s</font> could result in,     among other things, any of the following actions: warning letters; fines and     other civil penalties; unanticipated <font color="blue">expenditures</font>; delays in approving or     refusal  to  approve  a  <font color="blue">product candidate</font>; product recall or seizure;     <font color="blue">interruption</font> of <font color="blue">manufacturing</font> or <font color="blue">clinical trials</font>; operating <font color="blue">restrictions</font>;     <font color="blue">injunctions</font>; and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">product candidate</font>s</font> cannot be marketed in the <font color="blue"><font color="blue">United States</font> </font>without     FDA approval or clearance</td>
    </tr>
    <tr>
      <td>The FDA has <font color="blue">approved only two</font> of our product     <font color="blue">candidates</font>, Nascobal nasal gel and Nascobal <font color="blue">nasal spray</font>, and <font color="blue">cleared only</font>     one, our MASCT device, for sale in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our other product     <font color="blue">candidates</font> are in <font color="blue">development</font>, and will have to be <font color="blue">approved by</font> <font color="blue">the FDA     </font>before they can be marketed in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining FDA </font>approval     requires substantial time, effort, and <font color="blue">financial resources</font>, and may be     subject to both expected and <font color="blue">unforeseen delays</font>, including <font color="blue">without limitation</font>     citizen’s petitions or other <font color="blue">filings with</font> the FDA, and there can be no     assurance that any approval will be granted on a <font color="blue">timely basis</font>, if at all or     that delays will be resolved favorably or in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">the FDA     </font>does not approve our <font color="blue"><font color="blue">product candidate</font>s</font> in a <font color="blue">timely fashion</font>, or does not     <font color="blue">approve them at</font> all, our business and <font color="blue">financial condition may</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We,  our  <font color="blue">collaboration</font> partners, or the FDA may suspend or     terminate human <font color="blue">clinical trials</font> at any time <font color="blue">on various grounds</font>, including a     finding that the patients are being exposed to an unacceptable <font color="blue">health risk</font></td>
    </tr>
    <tr>
      <td>In addition, both before and after <font color="blue"><font color="blue">regulatory</font> approval</font>, we, our     <font color="blue">collaboration</font> partners, and our <font color="blue"><font color="blue">product candidate</font>s</font> are subject to numerous     FDA <font color="blue"><font color="blue">requirement</font>s</font> covering, among other things, testing, <font color="blue">manufacturing</font>,     quality control, labeling, advertising, promotion, <font color="blue">distribution</font>, and export</td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue"><font color="blue">requirement</font>s</font> may change and <font color="blue">additional</font> <font color="blue"><font color="blue">government</font> regulation</font>s may     be promulgated that <font color="blue">could affect us</font>, our <font color="blue">collaboration</font> partners, and our     <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood, nature or extent of     <font color="blue">government</font>  regulation  that  may  arise  from  future  <font color="blue">legislation</font> or     administrative action, either in the <font color="blue"><font color="blue">United States</font> </font>or abroad</td>
    </tr>
    <tr>
      <td>There can be     no assurance that we will not be required to incur <font color="blue">significant</font> costs to     <font color="blue">comply with such laws</font> and <font color="blue">regulations</font> in the future or that such laws or     <font color="blue">regulations</font> will not have a material adverse effect upon our business</td>
    </tr>
    <tr>
      <td>In addition, some of our <font color="blue"><font color="blue">product candidate</font>s</font>, such as our morphine     gluconate, will be subject to the <font color="blue"><font color="blue">requirement</font>s</font> of the Controlled Substances     Act and <font color="blue">implementing</font> <font color="blue">regulations</font> thereunder, which are <font color="blue"><font color="blue">administer</font>ed</font> by the     <font color="blue">DEA Establishments </font>may not <font color="blue">handle controlled drug substances until</font> they     have  been  inspected  and <font color="blue">registered by</font> the <font color="blue">DEA The DEA </font><font color="blue">also imposes</font>     <font color="blue">recordkeeping</font> and reporting <font color="blue"><font color="blue">requirement</font>s</font>,                                         28       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font><font color="blue">procurement</font>  and  <font color="blue">manufacturing</font>  quotas, sales <font color="blue">restrictions</font>, and other     <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Facilities </font>must be equipped to meet DEA security <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We currently hold a DEA <font color="blue">registration</font> to <font color="blue">conduct research at both</font> of our     Hauppauge,  NY  and  Bothell, <font color="blue">Washington </font><font color="blue">facilities</font> relating to drug     <font color="blue">formulations containing</font> DEA <font color="blue">controlled substances</font></td>
    </tr>
    <tr>
      <td>However, there can be no     assurance that we will be able to maintain our DEA <font color="blue">registration</font> or that we     will be able to obtain <font color="blue">additional</font> <font color="blue">registration</font>s required to continue to     research or <font color="blue">commercially</font> distribute our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>Our patent <font color="blue">application</font>s may be inadequate in terms of priority, scope or     <font color="blue">commercial value</font></td>
    </tr>
    <tr>
      <td>We apply for <font color="blue">patents covering</font> our <font color="blue">discoveries</font> and <font color="blue">technologies</font> as we     deem <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>However, we may fail to apply for <font color="blue">patents on important</font>     <font color="blue">discoveries</font> or <font color="blue">technologies</font> in a <font color="blue">timely fashion</font> or at all</td>
    </tr>
    <tr>
      <td>Also, our pending     patent <font color="blue">application</font>s may not result in the issuance of any patents</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">application</font>s may not be sufficient to meet the statutory <font color="blue"><font color="blue">requirement</font>s</font> for     <font color="blue">patentability</font>, and therefore we may be unable to obtain <font color="blue">enforceable patents</font>     covering  the  related  <font color="blue">discoveries</font>  or  <font color="blue">technologies</font>  we  may want to     <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>In addition, because patent <font color="blue">application</font>s are maintained in     secrecy for <font color="blue">approximately</font> 18 months after filing, other <font color="blue">parties may</font> have     filed patent <font color="blue">application</font>s relating to <font color="blue">inventions</font> before our <font color="blue">application</font>s     covering  the  same or similar <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In addition, foreign patent     <font color="blue">application</font>s are often published initially in <font color="blue">local languages</font>, and until an     English <font color="blue">language translation</font> is available it can be impossible to determine     the significance of a <font color="blue"><font color="blue">third party</font> invention</font></td>
    </tr>
    <tr>
      <td>Any patent <font color="blue">application</font>s filed     by third <font color="blue">parties may</font> prevail over our patent <font color="blue">application</font>s or may result in     patents that <font color="blue">issue alongside patents issued</font> to us, leading to <font color="blue">uncertainty</font>     over  the  scope of the patents or the freedom to practice the claimed     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Although we have a number of <font color="blue">issued patents</font>, the <font color="blue">discoveries</font> or     <font color="blue">technologies</font>  <font color="blue">covered by</font> these <font color="blue">patents may</font> not have any <font color="blue">therapeutic</font> or     commercial  value</td>
    </tr>
    <tr>
      <td>Also,  <font color="blue">issued patents</font> may not provide <font color="blue">commercially</font>     <font color="blue"><font color="blue">meaningful</font> protection against <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">parties may</font> be able to     <font color="blue">design around</font> our <font color="blue">issued patents</font> or <font color="blue">in<font color="blue">dependent</font>ly</font> develop products having     effects  similar  or  identical to our patented <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>In     addition, the scope of our patents is subject to considerable <font color="blue">uncertainty</font>     and <font color="blue">competitors</font> or other <font color="blue">parties may</font> obtain similar patents of uncertain     scope</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our products after FDA approval is subject to     <font color="blue">exclusivity periods provided by law</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under US </font>law, the FDA awards 180 days of <font color="blue">market exclusivity</font> to the     first generic <font color="blue">manufacture</font>r who <font color="blue">challenges</font> the patent of a <font color="blue">branded product</font></td>
    </tr>
    <tr>
      <td>However,  <font color="blue">amendments</font>  to  the  Hatch-Waxman Act will affect the future     <font color="blue">availability</font> of this <font color="blue">market exclusivity</font> in many cases</td>
    </tr>
    <tr>
      <td>These <font color="blue">amendments</font> now     require <font color="blue">generic applicants</font> to launch their <font color="blue">products within certain</font> time     frames or risk losing the <font color="blue">marketing exclusivity</font> that they had <font color="blue">gained through</font>     being a first-to-file applicant</td>
    </tr>
    <tr>
      <td>Apotex has filed a generic <font color="blue">application</font> for     its  intranasal  salmon-calcitonin product with a <font color="blue">filing date</font> that has     <font color="blue">priority over</font> our ANDA for our generic calcitonin-salmon intra<font color="blue">nasal spray</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">amendments</font> to the Hatch-Waxman Act do not apply to the Apotex intranasal     salmon-calcitonin product, which preceded the adoption of such <font color="blue">amendments</font></td>
    </tr>
    <tr>
      <td>Consequently, the Apotex <font color="blue">filing prevents us from marketing</font> our product until     180 days after Apotex <font color="blue">commences marketing</font> its product</td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2002,     Novartis brought a <font color="blue">patent infringement action against</font> Apotex claiming that     Apotex’s  intranasal salmon-calcitonin product infringes on Novartis’s     patents, seeking damages and <font color="blue">requesting injunctive relief</font></td>
    </tr>
    <tr>
      <td>That action is     <font color="blue">still pending</font></td>
    </tr>
    <tr>
      <td>We are unable to predict what, if any, effect the <font color="blue">Novartis  </font>   <font color="blue">action will</font> have on Apotex’s ability or plans to <font color="blue">commence marketing</font> its     product,  nor  can  we determine when, if at all, Apotex <font color="blue">will commence</font>     marketing its product</td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>Our operating results are subject to <font color="blue">significant</font> <font color="blue">fluctuation</font>s and     <font color="blue">uncertainties</font>, and our failure to <font color="blue">meet <font color="blue">expectations</font></font> of <font color="blue">public market</font>     analysts or investors regarding operating results may cause our stock price     to decline</td>
    </tr>
    <tr>
      <td>Our operating results are subject to <font color="blue">significant</font> <font color="blue">fluctuation</font>s and     <font color="blue">uncertainties</font> due to a number of factors including, <font color="blue">among others</font>:         •  timing and <font color="blue">achievement</font> of <font color="blue">licensing <font color="blue">transactions</font></font>, including <font color="blue">milestones</font>     and other <font color="blue">performance factors associated with</font> these contracts;         •  time and <font color="blue">costs involved</font> in <font color="blue">patent prosecution</font> and <font color="blue">development</font> of our     <font color="blue"><font color="blue">proprietary</font> position</font>;         •  <font color="blue">continued scientific</font> progress and level of <font color="blue">expenditures</font> in our research     and <font color="blue"><font color="blue">development</font> programs</font>;         •  cost of <font color="blue">manufacturing</font> scale-up and <font color="blue">production batches</font>, including vendor     provided <font color="blue">activities</font> and costs;         •  time and <font color="blue">costs involved</font> in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s;         •  changes in <font color="blue">general economic conditions</font> and drug delivery <font color="blue">technologies</font>;         •  expiration of <font color="blue">existing patents</font> and related revenues; and          •  <font color="blue">new products</font> and <font color="blue">product enhancements</font> that we or our <font color="blue">competitors</font>     introduce</td>
    </tr>
    <tr>
      <td>As a result of these factors and other <font color="blue">uncertainties</font>, our operating     results have fluctuated <font color="blue">significant</font>ly in <font color="blue">recent years</font>, resulting in net     losses of dlra2dtta1 million in 2003, dlra28dtta6 in 2004 and dlra32dtta2 million in 2005</td>
    </tr>
    <tr>
      <td>Our revenues and operating results, <font color="blue">particularly</font> those reported on a     quarterly basis, <font color="blue">will continue</font> to fluctuate <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>This <font color="blue">fluctuation</font>     makes it <font color="blue">difficult</font> to forecast our operating results</td>
    </tr>
    <tr>
      <td>Therefore, we believe     that <font color="blue">quarterly comparisons</font> of our operating results may not be <font color="blue">meaningful</font>,     and you should not <font color="blue">rely on them as</font> an <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In addition, our operating results in a <font color="blue">future quarter</font> or <font color="blue">quarters may fall</font>     below the <font color="blue">expectations</font> of <font color="blue">public market</font> analysts or investors</td>
    </tr>
    <tr>
      <td>If this were     to occur, the price of our <font color="blue">stock could decline</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">adequately protect</font> our <font color="blue">proprietary</font> <font color="blue">technology</font> from legal     <font color="blue">challenges</font>, infringement or alternative <font color="blue">technologies</font>, this <font color="blue"><font color="blue">inability</font> will</font>     hurt our <font color="blue"><font color="blue">competitive</font> position</font> and <font color="blue"><font color="blue">negatively</font> impact</font> our operating results</td>
    </tr>
    <tr>
      <td>We specialize in the <font color="blue">intranasal delivery</font> of <font color="blue"><font color="blue">pharmaceutical</font> products</font>     and  rely  on  the  issuance of patents, both in the <font color="blue"><font color="blue">United States</font> </font>and     <font color="blue"><font color="blue">international</font>ly</font>,  for  protection  against  <font color="blue">competitive</font>  drug delivery     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we believe that we exercise the <font color="blue">necessary</font> due     diligence in our <font color="blue">patent filings</font>, our <font color="blue"><font color="blue">proprietary</font> position</font> is not established     until the <font color="blue">appropriate</font> <font color="blue">regulatory</font> authorities actually issue a patent, which     may take <font color="blue">over three years from initial filing</font> or may never occur</td>
    </tr>
    <tr>
      <td>Moreover, even the <font color="blue">established patent positions</font> of <font color="blue">pharmaceutical</font>     companies are <font color="blue"><font color="blue">generally</font> uncertain</font> and <font color="blue">involve complex legal</font> and factual     issues</td>
    </tr>
    <tr>
      <td>Although we believe our <font color="blue">issued patents</font> are valid, third <font color="blue">parties may</font>     infringe our patents or <font color="blue">may initiate proceedings challenging</font> the validity or     <font color="blue">enforceability</font> of our patents</td>
    </tr>
    <tr>
      <td>The issuance of a patent is not <font color="blue">conclusive as</font>     to its claim scope, validity or <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Challenges </font>raised in patent     <font color="blue">infringement litigation</font> we initiate or in <font color="blue">proceedings initiated by third</font>     parties  may  result  in <font color="blue">determinations</font> that our patents have not been     infringed or that they are invalid, unenforceable or otherwise subject to     <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>In the event of any such <font color="blue">determinations</font>, third <font color="blue">parties may</font> be     able to use the <font color="blue">discoveries</font> or <font color="blue">technologies</font> claimed in our <font color="blue">patents without</font>     <font color="blue">paying licensing fees</font> or royalties to us, <font color="blue">which could</font> <font color="blue">significant</font>ly diminish     the  value  of  these <font color="blue">discoveries</font> or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>As a result of such     <font color="blue">determinations</font>, we may be enjoined from pursuing research, <font color="blue">development</font> or     <font color="blue">commercialization</font>  of  <font color="blue">potential products</font> or may be required to obtain     licenses, if available, to the <font color="blue"><font color="blue">third party</font> patents</font> or to develop or obtain     alternative <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Responding </font>to <font color="blue">challenges</font> initiated by <font color="blue">third parties</font>     may require                                         30       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font><font color="blue">significant</font> <font color="blue">expenditures</font> and divert the attention of our <font color="blue">management</font> and key     <font color="blue">personnel from</font> other business concerns</td>
    </tr>
    <tr>
      <td>Furthermore,  it  is <font color="blue">possible others will infringe</font> or otherwise     <font color="blue">circumvent</font> our <font color="blue">issued patents</font> and that we will be unable to fund the cost of     <font color="blue">litigation against them</font> or that we would elect not to <font color="blue">pursue litigation</font></td>
    </tr>
    <tr>
      <td>In     addition,  enforcing  our  patents  against  third <font color="blue">parties may</font> require     <font color="blue">significant</font> <font color="blue">expenditures</font> <font color="blue">regardless</font> of the outcome of <font color="blue">such efforts</font></td>
    </tr>
    <tr>
      <td>We also     cannot  assure  you that others have not filed patent <font color="blue">application</font>s for     <font color="blue">technology</font> <font color="blue">covered by</font> our pending <font color="blue">application</font>s or that we were the first to     invent the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>There may also exist <font color="blue"><font color="blue">third party</font> patents</font> or patent     <font color="blue">application</font>s relevant to our <font color="blue">potential products</font> that may block or compete     with the <font color="blue">technologies</font> <font color="blue">covered by</font> our patent <font color="blue">application</font>s and <font color="blue">third parties</font>     may <font color="blue">in<font color="blue">dependent</font>ly</font> develop IP similar to our patented IP, <font color="blue">which could</font> result     in, among other things, interference proceedings in the <font color="blue"><font color="blue">United States</font> </font>Patent     and Trademark Office to determine priority of invention</td>
    </tr>
    <tr>
      <td>In addition, we may not be able to protect our established and pending     patent positions from <font color="blue">competitive</font> drug delivery <font color="blue">technologies</font>, which may     provide  more  effective <font color="blue">therapeutic</font> benefit to patients and which may     therefore make our products, <font color="blue">technology</font> and <font color="blue"><font color="blue">proprietary</font> position</font> obsolete</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">adequately protect</font> our <font color="blue">proprietary</font> <font color="blue">technology</font> from     legal <font color="blue">challenges</font>, infringement or alternative <font color="blue">technologies</font>, we will not be     able to <font color="blue">compete <font color="blue">effectively</font></font> in the <font color="blue">pharmaceutical</font> delivery business</td>
    </tr>
    <tr>
      <td>Because <font color="blue">intellectual property rights</font> are of limited duration, expiration of     <font color="blue">intellectual property rights</font> and licenses will <font color="blue"><font color="blue">negatively</font> impact</font> our     operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property rights, such as patents and license <font color="blue"><font color="blue">agreement</font>s</font>     <font color="blue">based on</font> those patents, <font color="blue">generally</font> are of limited duration</td>
    </tr>
    <tr>
      <td>Our operating     results <font color="blue">depend on</font> our patents and IP licenses</td>
    </tr>
    <tr>
      <td>Therefore, the expiration or     other loss of rights associated with <font color="blue">IP and IP </font>licenses can <font color="blue">negatively</font>     impact our business</td>
    </tr>
    <tr>
      <td>Our product <font color="blue"><font color="blue">development</font> efforts</font> may not result in <font color="blue"><font color="blue">commercial product</font>s</font></td>
    </tr>
    <tr>
      <td>Our future results of <font color="blue">operations</font> depend, to a <font color="blue">significant</font> degree, upon     our and our <font color="blue">collaboration</font> partners’ ability to <font color="blue">successfully</font> <font color="blue">commercialize</font>     <font color="blue">additional</font> <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">commercialization</font>     process, <font color="blue">particularly</font> with respect to <font color="blue">innovative products</font>, is both time     consuming and costly and involves a high degree of business risk</td>
    </tr>
    <tr>
      <td><font color="blue">Successful     </font>product <font color="blue">development</font> in the <font color="blue">pharmaceutical</font> industry is <font color="blue">highly uncertain</font>, and     very few research and <font color="blue">development</font> projects result in a <font color="blue">commercial product</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that appear promising in the <font color="blue">early phases</font> of <font color="blue">development</font>,     such as in early human <font color="blue">clinical trials</font>, may fail to reach the market for a     number of reasons, such as:         •  a <font color="blue">product candidate</font> may not perform as expected in later or broader     trials in humans and <font color="blue">limit marketability</font> of such <font color="blue">product candidate</font>;         •  <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s may not be obtained in a <font color="blue">timely manner</font>,     if at all;         •  a <font color="blue">product candidate</font> may not be able to be <font color="blue">successfully</font> and profitably     produced and marketed;         •  third <font color="blue">parties may</font> have <font color="blue"><font color="blue">proprietary</font> rights</font> to a <font color="blue">product candidate</font>, and     do not <font color="blue">allow sale on reasonable terms</font>;          •  a <font color="blue">product candidate</font> may not be <font color="blue">financially successful</font> because of     existing <font color="blue">therapeutic</font>s that <font color="blue">offer equivalent</font> or <font color="blue">better treatments</font>; or          •   suppliers of <font color="blue">product pumps</font> or <font color="blue">actuators</font> required to atomize our     <font color="blue">formulations may increase</font> their price or cease to <font color="blue">manufacture</font> them without     prior notice</td>
    </tr>
    <tr>
      <td>To date, except for our Nascobal nasal gel and Nascobal <font color="blue">nasal spray</font>     (the new drug <font color="blue">application</font>s (each, an “NDA”) for which have been transferred     to  QOL),  none  of our other <font color="blue"><font color="blue">product candidate</font>s</font> utilizing our current     intranasal  drug  delivery  <font color="blue">technology</font>  have been <font color="blue">approved by</font> <font color="blue">the FDA     </font>Accordingly, there can be no assurance that any of our <font color="blue"><font color="blue">product candidate</font>s</font>     currently in <font color="blue">development</font> will ever be <font color="blue">successfully</font> <font color="blue">commercialize</font>d, and     delays in any part of the process or our <font color="blue">inability</font> to obtain <font color="blue">regulatory</font>                                         31       _________________________________________________________________    [85]Table of <font color="blue">Contents       </font>approval  could  <font color="blue"><font color="blue">adversely</font> affect</font> our operating results <font color="blue">by restricting</font>     <font color="blue">introduction</font> of <font color="blue">new products</font> by us or our <font color="blue">collaboration</font> partners</td>
    </tr>
    <tr>
      <td>We have limited experience in marketing or selling our products, and we may     need to <font color="blue">rely on <font color="blue">marketing partner</font>s</font> or <font color="blue">contract sales companies</font></td>
    </tr>
    <tr>
      <td>Even if we are able to develop our products and obtain <font color="blue">necessary</font>     <font color="blue">regulatory</font>  approvals,  we  have limited experience or <font color="blue">capabilities</font> in     marketing or <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td>We currently have a limited     sales,  marketing and <font color="blue">distribution</font> infrastructure</td>
    </tr>
    <tr>
      <td>Accordingly, we are     <font color="blue">dependent</font>  on  our  ability to build this <font color="blue"><font color="blue">capability</font> ourselves</font> or find     <font color="blue">collaborative</font> <font color="blue">marketing partner</font>s or <font color="blue">contract sales companies</font> for commercial     sale of our internally-developed products</td>
    </tr>
    <tr>
      <td>Even if we find a potential     <font color="blue">marketing partner</font>, we may not be able to negotiate a <font color="blue">licensing contract on</font>     favorable terms to justify our <font color="blue">investment</font> or achieve <font color="blue">adequate revenues</font></td>
    </tr>
    <tr>
      <td>Coverage and <font color="blue">reimbursement</font> status of newly approved drugs is uncertain and     the failure to obtain adequate <font color="blue">reimbursement</font> coverage <font color="blue">could limit</font> our     ability to generate revenue</td>
    </tr>
    <tr>
      <td>Our  products  may prove to be <font color="blue">unsuccessful</font> if <font color="blue">various parties</font>,     including <font color="blue">government</font> health administration authorities, private healthcare     insurers  and  other  healthcare  payers,  such  <font color="blue">as health maintenance</font>     <font color="blue">organizations</font> and self-insured employee plans that determine <font color="blue">reimbursement</font>     to the consumer, do not accept our products for <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Sales of     <font color="blue">therapeutic</font> and other <font color="blue"><font color="blue">pharmaceutical</font> products</font> depend in <font color="blue">significant</font> part on     the <font color="blue">availability</font> of <font color="blue">reimbursement</font> to the <font color="blue">consumer from</font> these <font color="blue">third party</font>     payers</td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payers</font> are <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font>     for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">reimbursement</font>     will be <font color="blue">available at</font> all or <font color="blue">at levels sufficient</font> to allow our marketing     partners to achieve <font color="blue">profitable price levels</font> for our products</td>
    </tr>
    <tr>
      <td>If we fail to     achieve  adequate  <font color="blue">reimbursement</font> levels, patients may not purchase our     products and sales of these <font color="blue">products will</font> be absent or reduced</td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">defend lawsuits</font> or pay damages for <font color="blue">product liability</font>     claims</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">inherently exposes us</font> to potential <font color="blue">product liability</font>     claims</td>
    </tr>
    <tr>
      <td>We face substantial <font color="blue">product liability</font> exposure in <font color="blue">human clinical</font>     trials and for products that we sell, or <font color="blue">manufacture</font> for others to sell,     after <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>The risk exists <font color="blue">even with respect</font> to those drugs     that are <font color="blue">approved by</font> <font color="blue">regulatory</font> agencies for commercial <font color="blue">distribution</font> and     sale and <font color="blue">manufacture</font>d in <font color="blue">facilities</font> licensed and regulated by <font color="blue">regulatory</font>     agencies</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product liability</font> claims, <font color="blue">regardless</font> of their merits, could be     costly, divert <font color="blue">management</font>’s attention and <font color="blue"><font color="blue">adversely</font> affect</font> our reputation     and the demand for our products</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">product liability</font> <font color="blue">insurance coverage</font> in the amount     of  dlra10 million per occurrence and a dlra20 million aggregate limitation,     subject to a deductible of dlra10cmam000 per occurrence</td>
    </tr>
    <tr>
      <td>From time to time, the     <font color="blue">pharmaceutical</font> industry has experienced <font color="blue">difficult</font>y in obtaining product     <font color="blue">liability <font color="blue">insurance coverage</font></font> for <font color="blue">certain products</font> or coverage in the desired     amounts or with the desired <font color="blue">deductibles</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will     be able to obtain the levels or types of insurance we <font color="blue">would otherwise</font> have     obtained prior to these market changes or that the <font color="blue">insurance coverage</font> we do     obtain  will  not  contain  large <font color="blue">deductibles</font> or fail to <font color="blue">cover certain</font>     <font color="blue">liabilities</font> or that it <font color="blue">will otherwise cover</font> all <font color="blue">potential losses</font></td>
    </tr>
    <tr>
      <td>We may be unable to compete <font color="blue">successfully</font> against our current and future     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">drug industry</font> is intense</td>
    </tr>
    <tr>
      <td>Although we are not aware     of any other companies that have the scope of <font color="blue">proprietary</font> <font color="blue">technologies</font> and     processes that we have developed, there are a number of <font color="blue">competitors</font> who     possess <font color="blue">capabilities</font> relevant to the <font color="blue">drug <font color="blue">delivery field</font></font></td>
    </tr>
    <tr>
      <td>In particular, we     face substantial <font color="blue"><font color="blue">competition</font> from companies pursuing</font> the <font color="blue">commercialization</font>     of products using <font color="blue">intranasal drug</font> delivery <font color="blue">technology</font> such as Archimedes,     Intranasal Technologies, Inc, Aegis Therapeutics, Bentley Pharmaceuticals,     Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">IDDS Established </font><font color="blue">pharmaceutical</font> companies such as <font color="blue">AstraZeneca </font>and     <font color="blue">GlaxoSmithKline </font>plc also have in-house <font color="blue">intranasal drug</font> delivery research and     <font color="blue"><font color="blue">development</font> programs</font> that have <font color="blue">successfully</font> developed and are marketing     products using <font color="blue">intranasal drug</font> delivery <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We also                                         32       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font><font color="blue">face indirect <font color="blue">competition</font> from</font> other <font color="blue">companies with expertise</font> in alternate     drug  delivery  <font color="blue">technologies</font> such as oral, injectable, patch-based and     <font color="blue">pulmonary administration</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> include Alza, Alkermes, Nektar,     Skye Pharma, Unigene, Neose, Generex Bio<font color="blue">technology</font> Corporation and Emisphere     Technologies (Emisphere)</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face <font color="blue">competition</font></font> in the area of siRNA     <font color="blue">therapeutic</font>s from companies such as Alnylam Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Universities </font>and public and private research <font color="blue">institutions</font> are also     potential <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>While these <font color="blue">organizations</font> primarily have <font color="blue">educational</font>     <font color="blue">objectives</font>, they may develop <font color="blue">proprietary</font> <font color="blue">technologies</font> related to the drug     <font color="blue">delivery field</font> or <font color="blue">secure protection</font> that we may need for <font color="blue">development</font> of our     <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>We <font color="blue">may attempt</font> to license these <font color="blue">proprietary</font>     <font color="blue">technologies</font>, but these <font color="blue">licenses may</font> not be available to us on acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater capital resources,     research  and  <font color="blue">development</font>  resources  and  experience,  <font color="blue">manufacturing</font>     <font color="blue">capabilities</font>, <font color="blue">regulatory</font> expertise, sales and marketing resources, and     established <font color="blue">collaborating</font> <font color="blue">relationships</font> with <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font>, either alone or with their <font color="blue">collaboration</font> partners, may succeed     in developing drug delivery <font color="blue">technologies</font> that are similar or preferable in     <font color="blue">effectiveness</font>,  safety,  cost  and  ease of <font color="blue">commercialization</font>, and our     <font color="blue">competitors</font> may obtain IP protection or <font color="blue">commercialize</font> <font color="blue">such product</font>s sooner     than we do</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font><font color="blue">by others may</font> render our <font color="blue"><font color="blue">product candidate</font>s</font> or our     <font color="blue">technologies</font>  obsolete or, if developed <font color="blue">earlier than</font> our products, may     achieve <font color="blue">market acceptance</font> <font color="blue">which could</font> <font color="blue"><font color="blue">negatively</font> impact</font> the <font color="blue">opportunities</font>     for our products <font color="blue">regardless</font> of the merits of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we have a <font color="blue">problem with</font> our <font color="blue">manufacturing</font> <font color="blue">facilities</font>, we may not be able     to market our products or conduct <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>A substantial portion of our products for <font color="blue">both clinical</font> and commercial     use is, or will be <font color="blue">manufacture</font>d at our <font color="blue">facilities</font> in Hauppauge, New York,     and in Bothell, Washington</td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> capacity of the <font color="blue">New York     </font><font color="blue">facility</font>  is  <font color="blue">approximately</font>  6 million product units per year, and our     <font color="blue">manufacturing</font> capacity of the <font color="blue">Washington </font><font color="blue">facility</font> will be <font color="blue">approximately</font>     54 million product units per year</td>
    </tr>
    <tr>
      <td>If we have a <font color="blue">problem at either</font> of our     <font color="blue">manufacturing</font> <font color="blue">facilities</font>, it could cause a delay in <font color="blue">clinical trials</font> or the     supply of product to market</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> delay or failure to <font color="blue">manufacture</font>     <font color="blue">could jeopardize</font> our performance contracts with <font color="blue">collaboration</font> partners,     resulting  in material penalties to us and <font color="blue">jeopardizing</font> the commercial     viability of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> are subject to risks of <font color="blue">natural disasters</font> including     <font color="blue">earthquakes</font>  and  floods</td>
    </tr>
    <tr>
      <td>Although we have insurance, there can be no     assurance that any business <font color="blue">disruption</font> caused by a <font color="blue">natural disaster would</font> be     fully  reimbursed  or  that it would not delay our product <font color="blue">development</font>     processes</td>
    </tr>
    <tr>
      <td>Our current <font color="blue">facilities</font> are leased and there can be no assurance     that we will be able to <font color="blue">negotiate future lease extensions at reasonable</font>     rates</td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue">hazardous</font> chemicals</font> and <font color="blue">radioactive</font> and <font color="blue">biological materials</font> in our     business</td>
    </tr>
    <tr>
      <td>Any disputes relating to improper use, handling, storage or     disposal of these <font color="blue">materials could</font> be time-consuming and costly</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">operations</font> involve the use of <font color="blue">hazardous</font>,     <font color="blue">radioactive</font>  and biological, <font color="blue">potentially</font> infectious, materials</td>
    </tr>
    <tr>
      <td>We are     subject  to  the  risk of <font color="blue">accidental contamination</font> or discharge or any     <font color="blue">resultant injury from</font> these materials</td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local laws</font> and     <font color="blue">regulations</font> govern the use, <font color="blue">manufacture</font>, storage, handling and disposal of     these materials</td>
    </tr>
    <tr>
      <td>We could be subject to damages, fines and penalties in the     event of an improper or <font color="blue"><font color="blue">unauthorized</font> release</font> of, or exposure of <font color="blue">individuals</font>     to, these <font color="blue">hazardous</font> materials, and our <font color="blue">liability could exceed</font> our total     assets</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with environmental laws</font> and <font color="blue">regulations</font> may be expensive,     and current or future environmental <font color="blue">regulations</font> may impair our business</td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________    [87]Table of <font color="blue">Contents       </font>Reforms in the <font color="blue">healthcare industry</font> and the <font color="blue">uncertainty</font> associated with     <font color="blue">pharmaceutical</font> pricing, <font color="blue">reimbursement</font> and related matters could <font color="blue">adversely</font>     affect the marketing, pricing and demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font><font color="blue">expenditures</font> for healthcare have been the subject of     considerable  public  attention in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Both private and     <font color="blue">government</font> entities are <font color="blue">seeking ways</font> to reduce or <font color="blue">contain healthcare costs</font></td>
    </tr>
    <tr>
      <td>Numerous proposals that would effect changes in the <font color="blue"><font color="blue">United States</font> </font>healthcare     system  have <font color="blue">been introduced</font> or proposed in <font color="blue">Congress </font>and in some state     <font color="blue">legislatures</font>, including <font color="blue">reductions</font> in the cost of <font color="blue">prescription products</font> and     changes  in the <font color="blue">levels at which consumers</font> and <font color="blue">healthcare providers</font> are     reimbursed  for purchases of <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>For example, the     Medicare Prescription Drug, Improvement and Modernization Act of 2003 and     the proposed rules thereunder impose new <font color="blue"><font color="blue">requirement</font>s</font> for the <font color="blue">distribution</font>     and pricing of <font color="blue">prescription drugs</font> in 2004, <font color="blue">which could</font> reduce <font color="blue">reimbursement</font>     of <font color="blue">prescription drugs</font> for <font color="blue">healthcare providers</font> and insurers</td>
    </tr>
    <tr>
      <td>Although we     <font color="blue">cannot predict</font> the full effect on our business of the <font color="blue">implementation</font> of this     <font color="blue">legislation</font>, we believe that <font color="blue">legislation</font> that reduces <font color="blue">reimbursement</font> for our     products  could  <font color="blue">adversely</font> impact how much or under what <font color="blue">circumstances</font>     <font color="blue">healthcare providers</font> will prescribe or <font color="blue">administer</font> our products</td>
    </tr>
    <tr>
      <td>This could     <font color="blue">materially</font> and <font color="blue">adversely</font> impact our business by reducing our ability to     generate revenue, <font color="blue">raise capital</font>, obtain <font color="blue">additional</font> <font color="blue">collaborators</font> and market     our products</td>
    </tr>
    <tr>
      <td>In addition, we believe the increasing emphasis on managed     care in the <font color="blue"><font color="blue">United States</font> </font>has and <font color="blue">will continue</font> to <font color="blue">put pressure on</font> the price     and usage of our products, which may <font color="blue">adversely</font> impact product sales</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">key personnel</font>, or if we are unable to attract and retain     <font color="blue">additional</font> personnel, then we may be unable to <font color="blue">successfully</font> develop our     business</td>
    </tr>
    <tr>
      <td>If we are unable to retain one or more of our <font color="blue">corporate officers</font>,     Dr</td>
    </tr>
    <tr>
      <td>Paul H Johnson, Senior Vice President, Research     and  Development and Chief Scientific Officer, Philip C Ranker, Chief     Financial Officer and Corporate Secretary, David E Wormuth, Senior Vice     President, Operations, Timothy M Duffy, Executive Vice President, Marketing     and Business Development, or any of our other <font color="blue">key managers</font> or key technical     personnel, our business could be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Except for the <font color="blue">employment</font>     <font color="blue"><font color="blue">agreement</font>s</font>  with  Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Quay and Mr</font></td>
    </tr>
    <tr>
      <td>Ranker, we <font color="blue">generally</font> do not execute     <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> with members of our <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>Whether or not a     member of <font color="blue">management</font> has executed an <font color="blue">employment</font> <font color="blue">agreement</font>, there can be no     assurance that we will be able to retain our <font color="blue">key managers</font> or key technical     personnel or replace any of them if we lose their services for any reason</td>
    </tr>
    <tr>
      <td>Although we make a <font color="blue">significant</font> effort and allocate substantial resources to     recruit <font color="blue">candidates</font> to our <font color="blue">Washington </font>state and New York state offices,     <font color="blue">competition</font> for <font color="blue">competent managers</font> and <font color="blue">technical personnel</font> is intense</td>
    </tr>
    <tr>
      <td>Failure to retain our <font color="blue">key personnel</font> may compromise our ability to negotiate     and enter into <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font>, delay our ongoing     <font color="blue">discovery</font> research efforts, delay pre-clinical or clinical testing of our     <font color="blue"><font color="blue">product candidate</font>s</font>, delay the <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font> process</font> or prevent us from     <font color="blue">successfully</font> <font color="blue">commercializing</font> our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, if we have to replace any of these <font color="blue">individuals</font>, we may     not be able to <font color="blue">replace knowledge</font> that they have about our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">difficult</font>ies managing our growth, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>We  increased  the number of our full-time employees from 83 on     <font color="blue">December </font>31, 2003 to 140 on January 31, 2006, and we expect to continue to     grow to meet our strategic <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">growth continues</font>, it may place     a strain on us, our <font color="blue">management</font> and our resources</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">effectively</font>     manage our <font color="blue">operations</font>, growth and various projects requires us to continue     to improve our operational, financial and <font color="blue">management</font> controls, reporting     systems and procedures and to attract and retain <font color="blue">sufficient numbers</font> of     <font color="blue">talented employees</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> implement these tasks     on  a  <font color="blue">larger scale</font> and, <font color="blue">accordingly</font>, we may not achieve our research,     <font color="blue">development</font>  and  <font color="blue">commercialization</font>  goals</td>
    </tr>
    <tr>
      <td>If we fail to improve our     operational,  financial and <font color="blue">management</font> information systems, or fail to     <font color="blue">effectively</font> monitor or manage our new and <font color="blue">future employees</font> or our growth,     our business could suffer <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td><font color="blue">In                                         </font>34       _________________________________________________________________    [88]Table of <font color="blue">Contents       </font>addition, no assurance can be made that we will be able to <font color="blue">secure adequate</font>     <font color="blue">facilities</font> to house our staff, conduct our research or achieve our business     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">stock price will</font> not decline</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could be subject to <font color="blue">significant</font>     <font color="blue">fluctuation</font>s</td>
    </tr>
    <tr>
      <td>Among the factors that could affect our stock price are:         •  negative results from our clinical or pre-<font color="blue">clinical trials</font> or adverse     FDA decisions related to our <font color="blue"><font color="blue">product candidate</font>s</font> or <font color="blue">third party</font> products that     are in the same drug class as our products;         •  changes in revenue estimates or <font color="blue">publication</font> of research reports by     analysts or the decision of analysts to <font color="blue">drop coverage</font> of us;         •  failure to meet analysts’ revenue estimates;         •  <font color="blue">speculation</font> in the press or <font color="blue">investment</font> community;         •  <font color="blue">strategic actions by us</font> or our <font color="blue">competitors</font>, such as acquisitions or     <font color="blue">restructurings</font>;          •   actions  by  <font color="blue">institutional</font>  <font color="blue">stockholders</font>  and other <font color="blue">significant</font>     <font color="blue">stockholders</font>;         •  <font color="blue">low average daily trading volumes due</font> to <font color="blue">relatively</font> small number of     <font color="blue">shares outstanding</font>;         •  <font color="blue">general market conditions</font>; and          •   domestic  and  <font color="blue">international</font>  <font color="blue">economic factors unrelated</font> to our     performance</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">numerous factors</font> relating to our business may cause     <font color="blue">fluctuation</font>s or declines in our stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock markets</font> in general and the markets for <font color="blue">pharmaceutical</font> stocks     in particular, have experienced <font color="blue">extreme volatility</font> that has often been     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>This may in     part be related to the <font color="blue">increasing influence</font> of <font color="blue">hedge funds</font>, who can use     <font color="blue">stock shorting</font> and other <font color="blue">techniques</font> that <font color="blue">increase volatility</font></td>
    </tr>
    <tr>
      <td>These broad     market <font color="blue">fluctuation</font>s may <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">trading price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> number of shares of our <font color="blue">common stock</font> are subject to options     and warrants, and we expect to sell <font color="blue">additional</font> shares of our <font color="blue">common stock</font> in     the future</td>
    </tr>
    <tr>
      <td>Sales of these shares will dilute the interests of other     <font color="blue">security holders</font> and <font color="blue">may depress</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there were 20cmam750cmam477 shares of <font color="blue">common stock</font>     outstanding</td>
    </tr>
    <tr>
      <td>In addition, we may issue     <font color="blue">additional</font>  <font color="blue">common stock</font> and <font color="blue">warrants from</font> time to time to finance our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For  example, we completed <font color="blue">public offerings</font> of 1cmam725cmam000,     4cmam250cmam000 and 1cmam136cmam364 (and 511cmam364 warrants) shares of our <font color="blue">common stock</font> in     August 2005, <font color="blue">December </font>2004 and June 2004, respectively, to <font color="blue">raise capital</font> for     <font color="blue">general corporate purposes</font></td>
    </tr>
    <tr>
      <td>We may also issue <font color="blue">additional</font> shares to <font color="blue">fund potential acquisitions</font> or     in connection with <font color="blue">additional</font> <font color="blue">stock option</font>s or <font color="blue">restricted stock granted</font> to     our employees, officers, <font color="blue">directors</font> and <font color="blue">consultants under</font> our <font color="blue">stock option</font>     plans</td>
    </tr>
    <tr>
      <td>The issuance, perception that <font color="blue">issuance may</font> occur, or exercise of     warrants or <font color="blue">options will</font> have a <font color="blue">dilutive impact on</font> other <font color="blue">stockholders</font> and     could have a material negative effect on the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid cash</font> or <font color="blue">stock dividends on</font> our <font color="blue">common stock</font> and we do not     anticipate <font color="blue">paying dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">paid no cash</font> or <font color="blue">stock dividends on</font> any of our classes of     <font color="blue">common stock</font> to date, and we <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>,     if any, to fund the <font color="blue">development</font> and growth of our business</td>
    </tr>
    <tr>
      <td>35       _________________________________________________________________    [89]Table of <font color="blue">Contents       </font>The  terms  of  our current borrowing <font color="blue">facility</font> prohibit the payment of     <font color="blue">dividends without bank approval</font></td>
    </tr>
    <tr>
      <td>In addition, the terms of any <font color="blue">future debt</font>     or credit <font color="blue">facility</font> may preclude us from paying any dividends</td>
    </tr>
    <tr>
      <td>As a result,     capital <font color="blue">appreciation</font>, if any, of our <font color="blue">common stock</font> may be the sole source of     <font color="blue">potential gain</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The anti-takeover provisions of our <font color="blue">stockholder rights</font> plan may entrench     <font color="blue">management</font>, may delay or prevent <font color="blue">beneficial</font> takeover bids by <font color="blue">third parties</font>     and <font color="blue">may prevent</font> or frustrate any <font color="blue">stockholder attempt</font> to replace or remove     the current <font color="blue">management</font> even if the <font color="blue">stockholders</font> consider it <font color="blue">beneficial</font> to do     so</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">stockholder rights</font> plan designed to protect our <font color="blue">stockholders</font>     <font color="blue">from coercive</font> or <font color="blue">unfair takeover tactics</font></td>
    </tr>
    <tr>
      <td>Each <font color="blue">preferred stock purchase</font> right     entitles the holder to purchase from us 1/1000 of a share of Series A Junior     Participating Preferred Stock for dlra50</td>
    </tr>
    <tr>
      <td>In the event any acquiring entity or     group <font color="blue">accumulates</font> or initiates a <font color="blue">tender offer</font> to purchase 15prca or more of our     <font color="blue">common stock</font>, then each holder of a <font color="blue">preferred stock purchase</font> right, other     than  the  acquiring entity and its affiliates, will have the right to     receive, <font color="blue">upon exercise</font> of the <font color="blue">preferred stock purchase</font> right, shares of our     <font color="blue">common stock</font> or shares in the acquiring entity having a value equal to two     times the <font color="blue">exercise price</font> of the <font color="blue">preferred stock purchase</font> right</td>
    </tr>
    <tr>
      <td>The  intent  of  the  <font color="blue">stockholder rights</font> plan is to protect our     <font color="blue">stockholders</font>’ interests by encouraging anyone seeking control of our company     to  negotiate  with our board of <font color="blue">directors</font> (the “Board”)</td>
    </tr>
    <tr>
      <td>However, our     <font color="blue">stockholder rights</font> plan could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire  us  without the consent of the Board, even if doing so may be     <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>This plan may discourage, delay or prevent a     <font color="blue">tender offer</font> or <font color="blue">takeover attempt</font>, including offers or attempts that could     result in a <font color="blue">premium over</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>This plan     <font color="blue">could reduce</font> the price that investors might be willing to pay for shares of     our <font color="blue">common stock</font> in the future</td>
    </tr>
    <tr>
      <td>Furthermore, the anti-takeover provisions of     our  stockholder  rights plan may entrench <font color="blue">management</font> and make it more     <font color="blue">difficult</font> for <font color="blue">stockholders</font> to replace <font color="blue">management</font> even if the <font color="blue">stockholders</font>     consider it <font color="blue">beneficial</font> to do so</td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> in the supply of our raw and <font color="blue">bulk materials</font> needed to make     our <font color="blue">products could</font> cause our product <font color="blue">development</font> and <font color="blue">commercialization</font> to be     slowed or stopped</td>
    </tr>
    <tr>
      <td>We currently obtain supplies of <font color="blue">critical raw</font> and <font color="blue">bulk materials</font> used     in our research and <font color="blue">development</font> and <font color="blue">manufacturing</font> efforts from several     suppliers</td>
    </tr>
    <tr>
      <td>However, we do not have long-term contracts with any of these     suppliers</td>
    </tr>
    <tr>
      <td>While our existing <font color="blue">arrangements</font> supply sufficient quantities of     raw and <font color="blue">bulk materials</font> needed to accomplish the clinical <font color="blue">development</font> of our     product  <font color="blue">candidates</font>,  there can be no assurance that we would have the     <font color="blue">capability</font> to <font color="blue">manufacture</font> sufficient quantities of our <font color="blue"><font color="blue">product candidate</font>s</font> to     meet our needs if our suppliers are unable or unwilling to <font color="blue">supply such</font>     materials</td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">disruption</font> in the <font color="blue">availability</font> of raw or bulk     <font color="blue">materials could</font> slow or stop product <font color="blue">development</font> and <font color="blue">commercialization</font> of     the <font color="blue">relevant product</font></td>
    </tr>
    <tr>
      <td>Our dependence upon <font color="blue">third parties</font> for the <font color="blue">manufacture</font>     of our bottles, pumps, and <font color="blue">cap components</font> of our <font color="blue">intranasal products</font> and the     related supply chain may <font color="blue"><font color="blue">adversely</font> affect</font> our cost of goods, our ability to     develop and <font color="blue">commercialize</font> products on a timely and <font color="blue">competitive</font> basis, and     the <font color="blue">production volume</font> of our <font color="blue">intranasal products</font></td>
    </tr>
    <tr>
      <td>Failure of the Company’s <font color="blue">internal <font color="blue">control over</font> financial</font> reporting could     harm its business and financial results</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">management</font> is responsible for <font color="blue">establishing</font> and maintaining     adequate <font color="blue">internal <font color="blue">control over</font> financial</font> reporting</td>
    </tr>
    <tr>
      <td>Internal <font color="blue">control over</font>     financial reporting is a process to <font color="blue">provide <font color="blue">reasonable assurance</font></font> regarding     the <font color="blue">reliability</font> of financial reporting for <font color="blue">external purposes</font> in <font color="blue">accordance</font>     with  accounting principles <font color="blue">generally</font> accepted in the <font color="blue"><font color="blue">United States</font> </font>of     America</td>
    </tr>
    <tr>
      <td>Internal <font color="blue">control over</font> financial reporting includes maintaining     records  that  in  reasonable detail <font color="blue">accurately</font> and <font color="blue">fairly reflect</font> our     <font color="blue">transactions</font>; <font color="blue">providing reasonable</font> assurance that <font color="blue">transactions</font> are recorded     as  <font color="blue">necessary</font>  for  <font color="blue">preparation</font> of the financial statements; providing     <font color="blue">reasonable assurance</font> that receipts and <font color="blue">expenditures</font> of our assets are made     in  <font color="blue">accordance</font> with <font color="blue">management</font> authorization; and <font color="blue">providing reasonable</font>     assurance that <font color="blue">unauthorized</font>                                         36       _________________________________________________________________    [90]Table of <font color="blue">Contents       </font>acquisition, use or <font color="blue">disposition</font> of our assets that could have a material     effect on the <font color="blue">financial statements would</font> be prevented or detected on a     <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Because of its inherent <font color="blue">limitations</font>, internal <font color="blue">control over</font>     financial reporting is not intended to provide absolute assurance that a     <font color="blue">misstatement</font> of our <font color="blue">financial statements would</font> be prevented or detected</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">rapid growth</font> and entry into <font color="blue">new products</font> and <font color="blue">markets will</font> place <font color="blue">significant</font>     <font color="blue">additional</font>  pressure  on our system of <font color="blue">internal <font color="blue">control over</font> financial</font>     reporting</td>
    </tr>
    <tr>
      <td>Any failure to maintain an <font color="blue">effective system</font> of <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting <font color="blue">could limit</font> our ability to report our financial     results <font color="blue">accurately</font> and timely or to detect and <font color="blue">prevent fraud</font></td>
    </tr>
  </tbody>
</table>